Company: BDRX
Filing Date: 2025-11-17
Form Type: POS AM
Source: 0001214659-25-016809
Chunk: 26

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: POS AM
Chunk 26
---
 Capital

Since January 1, 2022, our issued share
capital has changed as provided below.

On March 22, 2022, we issued one Ordinary
Share upon the exercise of one warrant issued in February 2019 to a certain institutional investor at an exercise price of £200
per share.

On May 3, 2022, we issued 1,250 Ordinary
Shares to be purchased under our Share Incentive Plan at £0.02 per share to the trust of our Share Incentive Plan.

On August 3, 2022, we issued warrants to
purchase 16,666 Ordinary Shares to a certain institutional investor at an exercise price of £2.70 per share.

On September 26, 2022, we effected a ratio
change to the Depositary Shares, pursuant to which the ratio of Ordinary Shares to Depositary Shares was changed such that one Depositary
Share represented 25 Ordinary Shares. Our Ordinary Shares were not affected by this change and no fractional Depositary Shares were issued.

On December 16, 2022, we sold to an
institutional investor 492,400 Ordinary Shares represented by four Depositary Shares in a registered direct offering at $80,000.00 per
Depositary Share, resulting in gross proceeds of approximately $0.4 million.

On February 15, 2023, we completed
the closing of a private placement, or the February Private Placement, pursuant to which we sold to certain institutional investors (1)
3,250,000 Ordinary Shares represented by 32 Depositary Shares at $46,400.00 per Depositary Share, (2) 12,931,020 Ordinary Shares
represented by 129 Depositary Shares, issuable upon the exercise of Series A warrants, or Series A Warrants, issued in the February Private
Placement at an exercise price of $53,600.00 per warrant, (3) 19,396,400 Ordinary Shares represented by 193 Depositary Shares, issuable
upon the exercise of Series B warrants, or Series B Warrants, issued in the February Private Placement at an exercise price of $55,360.00
per warrant, and (4) 62,184,525 Ordinary Shares represented by 621 Depositary Shares, issuable upon the exercise of pre-funded warrants
issued in the February Private Placement at an exercise price of $8.00 per warrant, for aggregate gross proceeds of approximately
$6.0 million.